Period
recent search
Showing: 1 – 05 of 156 Regulated Information
07 November 2024
07 November 2024
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
09 October 2024
09 October 2024
18 September 2024
18 September 2024
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
PARIS, FRANCE, 16 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today final data from the CABINET Phase III trial investigating Cabometyx® (cabozantinib) versus placebo in people living with advanced pancreatic neuroendocrine tumors (pNETs) or advanced extra-pancreatic neuroendocrine tumors…
16 September 2024
16 September 2024
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
PARIS, FRANCE, 16 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today final data from the CABINET Phase III trial investigating Cabometyx® (cabozantinib) versus placebo in people living with advanced pancreatic neuroendocrine tumors (pNETs) or advanced extra-pancreatic neuroendocrine tumors…
15 September 2024
15 September 2024
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
PARIS, FRANCE, 15 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today detailed final overall survival (OS) data from the Phase III CONTACT-02 trial investigating the combination of Cabometyx® (cabozantinib) and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC). The…